Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR‐TKIs in advanced non‐small cell lung cancer: A systematic review and network meta‐analysis
Abstract Background The combination of antiangiogenic agents with epidermal growth factor receptor inhibitors (EGFR‐TKIs) and chemotherapy with EGFR‐TKIs are the most common combination treatment options in epidermal growth factor receptor (EGFR) positive non‐small cell lung cancer (NSCLC). This net...
Main Authors: | Jiali Dai, Xinyin Liu, Jun Li, Tianyu Qu, Yanan Cui, Shidai Jin, Erbao Zhang, Renhua Guo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-02-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14783 |
Similar Items
-
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
by: Lan-Lan Pang, et al.
Published: (2023-01-01) -
Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
by: Alicia González, et al.
Published: (2021-06-01) -
The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study
by: Yu Feng, et al.
Published: (2022-09-01) -
Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy
by: Amit Kumar Rajora, et al.
Published: (2020-06-01) -
Anlotinib plus chemotherapy for T790M‐negative EGFR‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial
by: Juan Li, et al.
Published: (2022-12-01)